ZOL treatments also augmented p53 expression levels in mesothelioma bearing the wild-type p53 gene and the increased p53 expression contributed to synergistic combinatory cytotoxicity by ZOL and CDDP (Okamoto et al. 2013). This evidence concerns the gene TP53 and mesothelioma.